GlassScriptPhysician profile
Thomas G Letourneau
NPI 1780688069
$3,730.86
in general payments reported to CMS, 2019-2025
12 companies · $375 in 2025
The $375 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,179 · 2020: $292 · 2021: $528 · 2022: $145 · 2023: $646 · 2024: $567 · 2025: $375.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,588.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,587.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $942.25 | 2019-2025 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $849.11 | 2019-2024 | Rexulti |
| Axsome Therapeutics, INC. | $506.99 | 2023-2025 | Auvelity |
| Abbvie INC. | $468.50 | 2021-2023 | |
| Allergan, INC. | $436.46 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $286.47 | 2021-2023 | |
| Lundbeck LLC | $80.19 | 2019 | |
| Ironshore Pharmaceuticals INC. | $44.89 | 2019 | |
| Shire North American Group INC | $43.95 | 2019 | |
| Neurocrine Biosciences, INC. | $29.17 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $26.81 | 2019 | |
| Sunovion Pharmaceuticals INC. | $16.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Letourneau listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.